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Marion Fehlker1†, Matthew R Huska2,3†, Thomas Jöns4, Miguel A Andrade-Navarro2 and Wolfgang Kemmner1*Abstract
Background: This study aimed at the identification of prognostic gene expression markers in early primary
colorectal carcinomas without metastasis at the time point of surgery by analyzing genome-wide gene expression
profiles using oligonucleotide microarrays.
Methods: Cryo-conserved tumor specimens from 45 patients with early colorectal cancers were examined, with the
majority of them being UICC stage II or earlier and with a follow-up time of 41–115 months. Gene expression
profiling was performed using Whole Human Genome 4x44K Oligonucleotide Microarrays. Validation of microarray
data was performed on five of the genes in a smaller cohort.
Results: Using a novel algorithm based on the recursive application of support vector machines (SVMs), we
selected a signature of 44 probes that discriminated between patients developing later metastasis and patients
with a good prognosis. Interestingly, almost half of the genes was related to the patients’ immune response and
showed reduced expression in the metastatic cases.
Conclusions: Whereas up to now gene signatures containing genes with various biological functions have been
described for prediction of metastasis in CRC, in this study metastasis could be well predicted by a set of gene
expression markers consisting exclusively of genes related to the MHC class II complex involved in immune
response. Thus, our data emphasize that the proper function of a comprehensive network of immune response
genes is of vital importance for the survival of colorectal cancer patients.
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Colorectal cancer (CRC) is one of the most common
cancers with an annual incidence of more than 400,000
new cases and 212,000 deaths in Europe alone [1]. Treat-
ment decisions are based on histopathological staging of
the primary tumor, considering depth of tumor infiltration
and metastatic spread to lymph nodes or distant organs.
Therapy consists of surgical resection of the tumor and
additional chemo- or/and radiotherapy in the case of
lymph node or distant metastases. Approximately 40%
of patients with CRC die within 5 years due to local* Correspondence: Wolfgang.Kemmner@charite.de
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reproduction in any medium, provided the orrecurrence or distant metastases. However, histopatho-
logical staging of the primary tumor does not allow for
outcome prediction, resulting in under- as well as over-
treatment of particular groups of patients.
The heterogeneity of patients with complex diseases
where the phenotype can have multiple genetic and en-
vironmental components [2,3] usually prevents one from
finding differentially expressed genes between different
groups of patients. Therefore, recent studies aimed at
outcome prediction based on gene expression [4-10],
often resulting in a diverse set of genes without a com-
mon biological function. In such a situation, specialized
methods of analysis for differential gene expression are
required. In particular, Zhang et al. [11] developed a
method appropriate for clinical data that iterativelyLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ating between different groups of patients, with patient
numbers similar to those in this study. Unlike methods
that attempt to select individual genes by their signifi-
cant differential expression between classes of samples
(e.g., SAM [12]), the gene set is selected as a set of
markers that discriminate when used collectively but not
necessarily when each gene is used individually. Using
this methodology we were able to identify a predictive
gene signature in an unbiased manner that shows a
functional relationship to tumor biology. Surprisingly,
most of the genes that were found to be informative for
patients’ metastasis were related to the immune system
but not to common tumor cell characteristics such as
angiogenesis, adhesion or invasion.
Methods
Patients
This study comprises only patients with early CRC of
UICC stages I-III, with the majority of them (76%) being
UICC stage II or earlier (Table 1). Inclusion criteria were:
CRC, R0 resection and follow-up of at least three years or
until disease recurrence. Exclusion criteria were: presence
of a secondary carcinoma, patient age less than 40 years
at the time of surgery, local recurrence, preoperative
treatment and radiotherapy.Table 1 Patient characteristics
Characteristic Non-recurrent Metachronous metastasis p-value1
absolute % absolute %








Female 14 42,4 8 66,7
Male 19 57,6 4 33,3
UICC stage n.s.
I 6 18,2 2 16,7
II 18 54,5 8 66,7
III 9 27,3 2 16,7
Location n.s.
Colon 14 42,4 5 41,7
Sigma 16 48,5 4 33,3
Rectum 3 9,1 3 25
1The given p-value refers to the significance of the correlation of the respective
characteristic with disease-free survival time and was calculated using a
two-sided t-test. n.s., not significant.Specimen characteristics
Cryo-conserved tumor specimens from 45 patients and
follow-up data were obtained from the Tumorbank of the
Charité Comprehensive Cancer Center (CCCC), Charité
Campus Buch, Berlin. Tissue samples from patients that
had undergone resection for sporadic colorectal adenocar-
cinoma at Charité Robert Roessle Hospital (1995–2006)
were enrolled for this study (after informed consent). The
study was approved by the local ethics committee (Charité
Universitätsmedizin Berlin). Archived primary tumor tis-
sues were collected immediately after surgical removal
and snap-frozen in liquid nitrogen according to internal
protocols. In addition to routine pathological examination
of the tumor tissue, histopathology of each sample used
for experimental analysis was reviewed by an experienced
pathologist to confirm diagnosis, tissue composition and
tumor content. Only non-necrotic tissue samples lacking
fatty or connective tissue and composed of at least 60%
tumor cells (mean: 73%) were processed. Disease-free time
was defined as the time period from the date of surgery to
confirmed distant tumor metastasis date for metastatic
cases and from the date of surgery to the date of last
follow-up for non-recurrent patients.Gene expression analysis
Total RNA was extracted from each frozen tumor speci-
men using the RNeasy Mini Prep Kit (Qiagen, Hilden,
Germany). RNA quality was checked by Bioanalyzer
(Agilent, Santa Clara, CA, USA). Only RNA samples
showing an RNA Integrity Number (RIN) of at least 7.0
were used for labelling. Total RNA (1 μg) was labeled
with Cy3 using the Low Input RNA Amplification Kit
(Agilent, Santa Clara, CA, USA). Labeled cRNAs were
hybridized to Whole Human Genome 4x44K Oligo-
nucleotide Microarrays (Agilent, Santa Clara, CA, USA)
following the manufacturer´s protocols. Arrays were
scanned by using standard Agilent protocols and a
G2565AA Microarray Scanner (Agilent, Santa Clara, CA,
USA). Raw expression values were determined using
Feature Extraction 8.0 software (Agilent, Santa Clara, CA,
USA). Data were uploaded to GEODataSets with acces-
sion: GSE31905 and ID: 200031905 under the title: Gene
expression profiling of colorectal carcinomas.Data analysis
Microarray data analysis was performed using R/
Bioconductor [13]. Raw expression values were nor-
malized using variance stabilization normalization [14],
and array quality was evaluated with the arrayQuality-
Metrics library [15]. Univariate differential expression
analysis was performed using methods from the limma
library [13], and multiple testing was controlled using
the Benjamini and Hochberg method [16]. Individual
Table 2 Annotations of genes with prognostic value in the prediction of CRC metastasis
Agilent probe
name
Gene symbol Gene name RefSeq GO immune1
A_23_P138635 BNIP3 BCL2/adenovirus E1B 19 kDa interacting
protein 3
NM_004052, NP_004043 Yes
A_23_P55270 CCL18 chemokine (C-C motif) ligand 18
(pulmonary and activation-regulated)
NM_002988, NP_002979 Yes
A_23_P70095 CD74 CD74 molecule, major histocompatibility




A_24_P131589 CD86 CD86 molecule NM_006889, NM_175862, NP_008820, NP_787058 Yes
A_24_P510357 CKAP2 cytoskeleton associated protein 2 NM_001098525, NM_018204, NP_001091995, NP_060674
A_23_P125278 CXCL11 chemokine (C-X-C motif) ligand 11 NM_005409, NP_005400 Yes
A_23_P18452 CXCL9 chemokine (C-X-C motif) ligand 9 NM_002416, NP_002407 Yes
A_23_P254944 GSTT1 glutathione S-transferase theta 1 NM_000853, NP_000844
A_23_P42306 HLA-DMA major histocompatibility complex,
class II, DM alpha
NM_006120, NP_006111 Yes
A_23_P258769 HLA-DPB1 major histocompatibility complex,
class II, DP beta 1
NM_002121, NP_002112 Yes
A_24_P370472 HLA-DRB4 major histocompatibility complex,
class II, DR beta 4




A_23_P31006 HLA-DRB5 major histocompatibility complex,
class II, DR beta 5
NM_002125, NP_002116 Yes
A_23_P112026 IDO1 indoleamine 2,3-dioxygenase 1 NM_002164, NP_002155 Yes
A_23_P119943 IGFBP2 insulin-like growth factor binding
protein 2, 36 kDa
NM_000597, NP_000588
A_23_P158817 IGHG1 immunoglobulin heavy locus
A_24_P92683 IGHA1 immunoglobulin heavy constant alpha 1 Yes
A_24_P204727 IGHG1 immunoglobulin heavy constant
gamma 1 (G1m marker)
A_24_P315941 IGHG1 immunoglobulin heavy constant
gamma 1 (G1m marker)
A_23_P21249 IGHG1 immunoglobulin heavy constant
gamma 1 (G1m marker)
A_24_P519504 IGL@ immunoglobulin lambda locus
A_24_P83102 IGLL1 immunoglobulin lambda-like
polypeptide 1
NM_020070, NM_152855, NP_064455, NP_690594 Yes
A_23_P76249 KRT6B keratin 6B NM_005555, NP_005546
A_23_P1691 MMP1 matrix metallopeptidase 1 (interstitial
collagenase)
NM_002421, NP_002412
A_23_P169494 ORM1 orosomucoid 1 NM_000607, NP_000598 Yes
A_23_P213508 PCSK1 proprotein convertase subtilisin/kexin
type 1
NM_000439, NP_000430
A_24_P174793 PCSK1 proprotein convertase subtilisin/kexin
type 1
NM_000439, NP_000430
A_23_P149517 PIGR polymeric immunoglobulin receptor NM_002644, NP_002635
A_24_P844984 PIGR polymeric immunoglobulin receptor NM_002644, NP_002635
A_23_P1962 RARRES3 retinoic acid receptor responder
(tazarotene induced) 3
NM_004585, NP_004576
A_23_P81898 UBD ubiquitin D NM_006398, NP_006389
1genes affiliated to the GO term “immune system process”.
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Table 3 GO-analysis of 44 signature genes
Biological process
GO ID
P-value Odds ratio Ex-pected Count Size GO Term Associated gene symbols
GO:0006955 1.4E-12 31.69 1.04 13 620 Immune response HLA-DMA, HLA-DPB1, HLA-DRB4,
HLA-DRB5, IGHA1, IGLL1, IDO1,
CXCL9, CCL18, CXCL11, BNIP3,
CD86, CD74
GO:0002376 4.6E-12 26.94 1.47 14 874 Immune system process HLA-DMA, HLA-DPB1, HLA-DRB4,
HLA-DRB5, IGHA1, IGLL1, IDO1,
CXCL9, ORM1, CCL18, CXCL11,
BNIP3, CD86, CD74
GO:0002504 1.8E-08 208.89 0.03 4 18 Antigen processing and presentation of




GO:0019882 3.5E-08 73.05 0.10 5 58 Antigen processing and presentation HLA-DMA, HLA-DPB1, HLA-DRB4,
HLA-DRB5, CD74
GO:0050896 3.6E-06 8.20 4.13 14 2454 Response to stimulus HLA-DMA, HLA-DPB1, HLA-DRB4,
HLA-DRB5, IGHA1, IGLL1, IDO1,
CXCL9, ORM1, CCL18, CXCL11,
BNIP3, CD86, CD74
GO:0002828 4.0E-05 327.34 0.01 2 6 Regulation of T-helper 2 type immune
response
IDO1, CD86
GO:0002682 6.7E-05 14.53 0.45 5 267 Regulation of immune system process HLA-DMA, IDO1, ORM1, CD86,
CD74
GO:0042092 1.2E-04 163.62 0.02 2 10 T-helper 2 type immune response IDO1, CD86
GO:0006954 1.4E-04 12.44 0.52 5 310 Inflammatory response IDO1, CXCL9, ORM1, CCL18,
CXCL11
GO:0030217 1.5E-04 34.98 0.10 3 62 T cell differentiation HLA-DMA, CD86, CD74
GO:0045058 1.8E-04 130.87 0.02 2 12 T cell selection HLA-DMA, CD74
GO:0006952 2.2E-04 8.75 0.93 6 550 Defense response IDO1, CXCL9, ORM1, CCL18,
CXCL11, BNIP3
GO:0045582 3.2E-04 93.45 0.03 2 16 Positive regulation of T cell differentiation HLA-DMA, CD86
GO:0045621 4.1E-04 81.76 0.03 2 18 Positive regulation of lymphocyte
differentiation
HLA-DMA, CD86
GO:0002460 4.7E-04 23.13 0.16 3 92 Adaptive immune response based on
somatic recombination of immune
receptors built from immunoglobulin
superfamily domains
HLA-DMA, IDO1, CD86
GO:0030098 4.7E-04 23.13 0.16 3 92 Lymphocyte differentiation HLA-DMA, CD86, CD74
GO:0002250 4.9E-04 22.88 0.16 3 93 Adaptive immune response HLA-DMA, IDO1, CD86
GO:0044419 5.8E-04 12.38 0.40 4 236 Interspecies interaction between
organisms
HLA-DRB4, MMP1, BNIP3, CD86
GO:0009611 7.2E-04 8.52 0.75 5 445 Response to wounding IDO1, CXCL9, ORM1, CCL18,
CXCL11
GO:0002694 8.8E-04 18.52 0.19 3 114 Regulation of leukocyte activation HLA-DMA, CD86, CD74
GO:0050865 1.0E-03 17.56 0.20 3 120 Regulation of cell activation HLA-DMA, CD86, CD74
GO:0045580 1.1E-03 46.67 0.05 2 30 Regulation of T cell differentiation HLA-DMA, CD86
GO:0051704 1.2E-03 7.57 0.84 5 498 Multi-organism process HLA-DRB4, IDO1, MMP1, BNIP3,
CD86
GO:0042110 1.4E-03 15.54 0.23 3 135 T cell activation HLA-DMA, CD86, CD74
GO:0050776 1.7E-03 14.54 0.24 3 144 Regulation of immune response HLA-DMA, IDO1, CD86
GO:0002822 1.8E-03 36.28 0.06 2 38 Regulation of adaptive immune response
based on somatic recombination of
immune receptors built from
immunoglobulin superfamily domains
IDO1, CD86
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Table 3 GO-analysis of 44 signature genes (Continued)
GO:0045619 1.8E-03 36.28 0.06 2 38 Regulation of lymphocyte differentiation HLA-DMA, CD86
GO:0002819 1.9E-03 35.29 0.07 2 39 Regulation of adaptive immune response IDO1, CD86
GO:0002521 1.9E-03 13.94 0.25 3 150 Leukocyte differentiation HLA-DMA, CD86, CD74
GO:0002684 1.9E-03 13.94 0.25 3 150 Positive regulation of immune system
process
HLA-DMA, IDO1, CD86
GO:0006935 2.1E-03 13.57 0.26 3 154 Chemotaxis CXCL9, CCL18, CXCL11
GO:0042330 2.1E-03 13.57 0.26 3 154 Taxis CXCL9, CCL18, CXCL11
GO:0007267 2.3E-03 6.50 0.97 5 576 Cell-cell signaling CXCL9, PCSK1, CCL18, CXCL11,
CD86
GO:0050870 3.5E-03 25.58 0.09 2 53 Positive regulation of T cell activation HLA-DMA, CD86
GO:0046649 4.2E-03 10.52 0.33 3 197 Lymphocyte activation HLA-DMA, CD86, CD74
GO:0051251 5.0E-03 21.37 0.11 2 63 Positive regulation of lymphocyte
activation
HLA-DMA, CD86
GO:0007626 5.5E-03 9.52 0.37 3 217 Locomotory behavior CXCL9, CCL18, CXCL11
GO:0009605 5.6E-03 5.20 1.20 5 710 Response to external stimulus IDO1, CXCL9, ORM1, CCL18,
CXCL11
GO:0030097 5.6E-03 9.43 0.37 3 219 Hemopoiesis HLA-DMA, CD86, CD74
GO:0002696 6.3E-03 18.88 0.12 2 71 Positive regulation of leukocyte activation HLA-DMA, CD86
GO:0050867 6.6E-03 18.34 0.12 2 73 Positive regulation of cell activation HLA-DMA, CD86
GO:0045321 6.8E-03 8.77 0.40 3 235 Leukocyte activation HLA-DMA, CD86, CD74
GO:0048534 7.1E-03 8.66 0.40 3 238 Hemopoietic or lymphoid organ
development
HLA-DMA, CD86, CD74
GO:0048583 7.2E-03 8.62 0.40 3 239 Regulation of response to stimulus HLA-DMA, IDO1, CD86
GO:0050863 8.1E-03 16.47 0.14 2 81 Regulation of T cell activation HLA-DMA, CD86
GO:0002520 8.4E-03 8.13 0.43 3 253 Immune system development HLA-DMA, CD86, CD74
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had a fold change greater than 2.0 and a false discovery
rate (q-value) less than 0.05. No significant differentially
expressed genes between recurrent and non-recurrent
samples were observed. Principal component analysis of
the data indicated that the full vectors of gene expres-
sion could not be used to discriminate between sample
classes (Additional file 1: Figure S1).
Multivariate feature selection was performed using the
R-SVM algorithm [11]. The algorithm was configured to
perform 100 bootstrapping cross-validation steps and
the best 42 probes were saved from each step. Probes
that were selected at least once were kept, yielding 44
probes that were considered for further analysis. We
then filtered out any probes that did not have an associ-
ated gene symbol (Table 2). The resulting 30 probes
were analyzed using the Bioconductor package GOstats
[17], which identified the GO term “immune system
process” (GO:0002376) associated to 14 of the genes as
being significantly (p-value 4.6E-12) enriched (Table 3).
ROC curves, Kaplan-Meier analysis and clinical meas-
ure statistics (Table 1) were calculated using SPSS 14
(SPSS, Chicago, IL, USA).Quantitative real-time PCR
Reverse transcription was performed using standard
protocols. Quantitative Real-Time PCR (TaqMan) was
carried out as described previously [18] using the fol-
lowing predesigned Assays-on-demand (Applied Biosys-
tems) with beta-Actin as housekeeping gene: ACTB (Hs
030023880_g1), CD74 (Hs 00959496_m1), HLA-DMA
(Hs 00157941_m1), CXCL11 (Hs 00171138_m1), CXCL9
(Hs 00970538_m1), IDO1 (Hs 00158032_m1). RT-PCR
was run in a 7000 Sequence Detection System (Applied
Biosystems) under the following conditions: 95°C for
10 minutes followed by 40 cycles of 95°C for 15 seconds
and 60°C for 1 minute. Data analysis was performed ac-
cording to the ΔΔCt method wherein β-Actin was used as
reference gene and colorectal carcinoma cells HT29 as
calibrator [19]. Significance of the differences in gene ex-
pression between samples of patients with or without later
metastasis as measured by qPCR were analyzed by Mann–
Whitney test using SPSS 14 (SPSS, Chicago, IL, USA).
Study design
This study includes retrospective cases, which were strati-
fied as to contain mainly UICC II cases. Samples were
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for at least 41 months or until metastasis of disease with a
follow-up time of 41–115 months (median: 77 months)
for non-recurrent patients. The clinical endpoint ex-
amined was distant metastasis of disease. The number
of samples initially available for this study was largely
reduced because of the application of stringent quality
criteria regarding sample characteristics, RNA and
microarray quality (see above) and stringent criteria
for the inclusion of patients.
Results
Microarray data analysis
Data analysis of gene expression profiles obtained by a
comprehensive genome-wide gene expression study using
oligonucleotide microarrays of 45 patients with CRCFigure 1 Clustering of the cohort using 14 selected immune response
gene expression signature composed of 14 genes related to the immune s
sample. Samples marked in blue are metastatic cases, samples marked in b
surgery. The length and the subdivision of branches display the relation of
genes. Most of the metastatic cases are grouped in the branch marked wit
genes expressed at low expression values (blue, low expression) than non-
have been scaled and centered row-wise.(Table 1) led to the identification of 44 probes that enabled
us to discriminate between patients with distant metastasis
during a follow-up time of 41 to 115 months after surgery
and those who did not (Table 2). Of the 44 probes, 30
were associated with genes that had functional annota-
tions including a gene symbol (using the hgug4112a
annotation package for Bioconductor, version 2.2.11).
GO-term enrichment analysis showed that the most
significantly enriched terms were “immune system process”,
associated with 14 genes, and “immune response”, associ-
ated with 13 genes, with the latter group being a subgroup
of the former (Table 3). Only 11 of the top 47 most
enriched GO terms were not directly related to immune
system processes, and some of those 11 GO terms such as
“response to stimulus”, “cell-cell signals”, and “taxis” might
be also related to immune response mechanisms.genes. Hierarchical clustering of 45 colorectal carcinomas, using a
ystem. Each row represents a probe set for a gene and each column a
right green are cases showing no metastasis at least 3 years after
the samples based on their similarity in the expression of the 14
h the asterisk (*). Metastatic cases have distinctly more of these 14
recurrent patients (red, high expression). The probe hybridization values
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The 14 genes associated to immune system processes were
used for further analysis. Hierarchical clustering of the
hybridization values of the corresponding 14 probes pro-
duced a branch that consisted of a majority of patients
with metachronous metastases (Figure 1). The analysis
suggests that the metastasized cases have more of these 14
genes expressed at low levels than non-recurrent patients,
although not always the same genes. In fact, all of the 14
genes in the immune related signature have average values
of expression that are lower in the set of metastasized
cases than in the set of non-recurrent patients (Figure 2).
According to these observations, we devised a simple
classifier using the hybridization values of the probes
associated to the 14 immune system related genes. If at
least a certain number of the 14 probes are below their
median hybridization values in all other samples, then
that sample is predicted to be metastatic. By ROC-curve
analysis of this gene signature (Figure 3), a cut-off of 8.5
probes was selected. This means that if at least 9 of the
putative marker probes show a value below their me-
dian expression value, then that sample is classified as a
case that would suffer later from metachronous metas-
tases. This cut-off yields a specificity of 79% and a sensi-
tivity of 75%.Figure 2 Normalized expression values. The expression values of the 14
Depicted are the normalized expression values for each of the immune resValidation of the microarray results
For validation of microarray results qPCR was performed
employing the five randomly chosen genes CD74, CXCL9,
CXCL11, HLA-DMA and IDO1 from the 14 immune sys-
tem related genes found by microarray analysis. Here, we
used a carefully selected collection of the previously
samples encompassing 11 patients which showed later
metastasis and 11 patients without metastasis during
the follow-up time which are similar in age, gender and
tumor staging (Table 4). The results of the qPCR ana-
lysis showed that the expression of these genes is lower
in cases with later metastasis for all of the examined genes,
thereby confirming the microarray results (Figure 4). Dif-
ferences in gene expression between both groups are sig-
nificant (less than 5%), except for CD74 which shows only
a trend into this direction.
Discussion
One characteristic feature of the current study is its
stringency with regard to sample collection and RNA/
microarray quality controls. Primary CRC can be divided
into two main groups, firstly tumors with chromosome
instability (CIN) showing high rates of chromosome
losses and gains and secondly tumors with microsatellite
instability (MSI) characterized by genome-wide changesimmune system-related genes were normalized and median centered.
ponse genes in non-recurrent (n = 33) and metastatic (n = 12) cases.
Figure 3 Predictive value of the immune response signature. (A) ROC-curve of a classifier for metastasis based on number of immune system
related probes (brown curve, 14 genes) expressed below the median of the whole set. A cut-off of 8.5 probes (marked with ) was selected based
on the ROC-curve shown in this figure (AUC = 0.817). This cut-off yields a specificity of 79% and a sensitivity of 75% (asymptotic significance = 0.001,
asymptotic 95% confidence interval = 0.678 – 0.956). For comparison, ROC-curves using one probe for each of the 30 selected genes (related or not to
immune response; green curve, 30 genes), or all their associated probes (one gene may have more than one associated probe; blue curve, 44 genes),
were not very different. (B) Kaplan Maier-Curve showing cumulated disease-free survival vs. disease-free survival time using the cut-off of 8.5 as
described in Figure 3; p = 0.002 (logRank Mantel-Cox), n = 45.
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match repair system [20]. Since these two groups of CRC
also differ in many aspects including survival of the pa-
tients [21], microsatellite instability of all tumors was
tested and MSI samples were excluded. This strategy thus
strengthens sample homogeneity.
Using a novel way of microarray data analysis (see Data
analysis section) a gene signature containing 44 probe setsTable 4 Patient characteristics of samples used for qPCR
validation
Characteristic Non-recurrent Metachronous metastasis p-value1
absolute % absolute %




Female 7 63,6 7 63,6
Male 4 36,3 4 36,3
UICC stage n.s.
I 2 18,2 2 18,2
II 8 72,7 7 63,6
III 1 9,1 2 18,2was identified (Table 2), which was predictive of cancer
metastasis. Almost half of the genes were related to im-
mune system processes and immune response. Obviously,
one may assume that not only the specific characteristics
of the tumor cells themselves, such as angiogenesis, inva-
sion, and proliferation or apoptosis, are relevant for metas-
tasis but also the immune response of the host organism.
In fact, it is clear that the host immune response is an im-
portant factor affecting cancer progression [22]. However,
the complex interplay between the tumor’s immunogen-
icity, the host’s immune response and the cancer cells’ cap-
abilities of evading immune response is still a challenging
subject of current research. CRCs are immunogenic and
provoke the host’s immune response, its strength being re-
lated to the patient’s prognosis [23]. High concentrations
of neutrophils [24], high preoperative levels of natural
killer cells [25], high numbers of mast cells [26,27], a high
percentage of CD4+ T cells [28], the infiltration of the
tumor with high numbers of central memory T cells and
high CD8+ T cell counts [29], for example, have been
found to correlate with a better prognosis. Yet, under the
selective pressure of the immune system, cancers “escape”
by becoming less immunogenic e.g. by failing to express
MHC class I antigens – a process called immunoediting
[30]. Apart from that, there is evidence that the cancer
itself has a direct immunosuppressive effect, which
Figure 4 (See legend on next page.)
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Figure 4 Validation of the marker gene expression by quantitative RT-PCR. Expression of five marker genes (IDO1, CXCL9, CD74, HLA-DMA,
CXCL11) in primary colorectal carcinomas with (always on the right side, REC = 1, n = 11) or without later metastasis (left side, REC = 0, n = 11) as
determined by qRT-PCR (TaqMan). Relative amount of expression is shown in Box – Whisker - Plots. Gray columns show a 50% range of the data
surrounding the median; black lines within each column mark the median; asterisks mark outliers. Differences between REC = 0 and REC = 1
groups are significant (less than 5%), except for CD74.
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to a basal shift in immune function [31].
Here, our analysis showed that our prognostic gene
signature of 44 genes includes 14 genes related to immune
response (Figure 1, Figure 2) that are down-regulated in
primary carcinomas which later metastasize. In general,
we hypothesize that the reduced expression of these 14
prognostic immune response genes impedes activation of
CD4 T-cells, mostly involving the MHC class II pathway.
Each of the 14 genes’ roles in this process is discussed in
the following section. Validation experiments using qPCR
confirmed downregulation of CD74, CXCL9, CXCL11,
HLA-DMA and IDO1.
Reduced expression of class II molecules might impede
activation of CD4 T cells
The ability of the immune system to recognize and defend
against the introduction of foreign antigens depends on
the ability of the host’s MHC class II, which presents
peptides degraded in intracellular vesicles to circulating
CD4 T cells. Class II molecules such as HLA-DMA are
immunological proteins vital to the proper loading and
presentation of these peptides in macrophages, immature
dendritic cells, B cells, and other antigen presenting cells.
HLA-DPB, HLA-DRB4, and HLA-DRB5 also belong to
this group. Here, a downregulation of components of the
MH) class II was found in primary carcinomas of patients
with later metastasizing tumors. In accordance, Lovig
et al. [32] found that patients positive for the HLA-DR
determinants showed better survival than those without
HLA-DR expression. Similarly, in MSI tumors with a good
prognosis an upregulation of HLA-DMA was noted [33].
Furthermore, HLA-DPB1 has been found to be downregu-
lated in metastasizing primary tumors of different origins,
including colorectum [34]. Down-regulation of four MHC
class II molecules has been reported to be significant for
primary tumors of hepatocellular carcinoma which show
later metastases [35]. Recently, the presence of inactivating
mutations in the HLA-A gene was reported for squamous
lung carcinomas [36].
Reduced expression of CD74, CD86, and CCL18 might
impede activation of CD4 T cells
CD74 (HLA-DR-associated invariant chain) plays a critical
role in MHC class II antigen processing by stabilizing
peptide-free class II alpha/beta heterodimers in a complex
soon after their synthesis and directing transport of thecomplex from the endoplasmic reticulum to compart-
ments where peptide loading of class II takes place.
CD86 (Cluster of Differentiation 86) is expressed on
antigen-presenting cells that provide co-stimulatory sig-
nals necessary for T cell activation and survival [37].
CCL18 is relevant for activation of T-cells through
MHC class II, and is a marker for tumor-associated
macrophages [38]. Moreover, it is a prognostic marker
in gastric cancer and probably plays a role in the physio-
logical homing of lymphocytes and dendritic cells as well
as in the generation of primary immune responses [39,40].
Reduced expression of CXCL9 and CXCL11 might impede
activation of T cells
CXCL9 and CXCL11 (Chemokine (C-X-C motif ) ligands
9 and 11) are small cytokines belonging to the CXC
chemokine family also known as “Monokine induced
by gamma interferon” [41]. They are produced by three
different cell types, monocytes, endothelial cells and
fibroblasts, play a role as T-cell chemoattractants and
are secreted in response to IFN-γ. Chemokines CXCL9,
CXCL10 and CXCL11 are closely related. All three genes
are located on human chromosome 4 and they all elicit
their chemotactic functions by interacting with the che-
mokine receptor CXCR3.
A conflicting result concerning IDO1
(Indoleamine-2,3-Dioxygenase)
Elevated tryptophan catabolism in the urine and blood
of tumor-bearing patients has been recognized for many
decades. For example, biopsy samples taken from CRC
patients show an overexpression of IDO1 [42]. Although
expression did not correlate with patient survival, increased
IDO1 expression did correlate with liver metastasis.
However, another study in patients with HCC showed
that IDO1 expression in tumor specimens was positively
correlated with progression-free survival [43]. More-
over, a significant inverse correlation between the dens-
ity of IDO1-positive microvessels and the number of
proliferating tumor cells in primary and metastatic renal
cell carcinoma was found [44]. Increased expression of
IDO1 in endothelial cells of tumors correlated positively
with long-term patient survival. Thus, these data sug-
gest that IDO1 can limit tumor growth. Similarly, in our
study we found an increase of IDO1 expression in pri-
mary carcinomas with good prognosis. The opposing
effects of IDO1 have been discussed recently [45].
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set of genes of prognostic relevance is in agreement with
other studies. CXCL9 and CXCL11 – as well as IDO1 -
are part of a published prognostic signature that predicts
metastasis in CRC [46]. Using Affymetrix arrays Lin et al.
aimed to develop gene classifiers to predict colorectal
cancer metastasis. Eleven of 19 genes in the classifier
were involved in the immune response. In agreement
with our results all of the 11 immune response genes
were down-regulated in metastatic cases [46]. Accord-
ingly, a comprehensive study using different assays with
the aim to elucidate the mechanisms underlying im-
mune response in CRC showed that a high expression
of CXCL9 and CXCL10 is correlated with a favorable
outcome of this disease [47]. Furthermore, CXCL9 and
IDO1 have been shown to be prognostic markers in
breast cancer [48]. Only recently, 15 immune response
genes, among them IGHA1, IGHG1 and IGL@ were
found to be part of a 128 genes signature that predicted
metastasis in CRC [8].Conclusions
Whereas up to now only gene signatures containing
genes of various biological functions have been described
for prediction of metastasis in CRC, in this study metas-
tasis could be well predicted by a set of gene expression
markers consisting exclusively of genes related to the
MHC class II complex clearly involved in immune re-
sponse. From our data we cannot state whether the later
recurring tumor is the cause or the beneficiary of the
suppressed immune response. Nevertheless, our data
show that the proper function of a comprehensive net-
work of immune response genes is of vital importance
for the survival of colorectal cancer patients. Recent re-
sults indicating that the tumor microenvironment can
reduce the maturation of dendritic cells [49,50] hint to
the importance of our findings and suggest avenues for
prognosis and treatment.Additional file
Additional file 1: Figure S1. Principal component analysis of the
microarray data used in this study.Abbreviations
CRC: Colorectal cancer; GO: Gene ontology; SVM: Support vector machine.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Conception and design: MAA and WK; data acquisition: MF and TJ; data
analysis and interpretation: MRH, MF, TJ and WK; manuscript writing: MF,
MAA and WK. All authors read and approved the final manuscript.Acknowledgements
The authors are particularly grateful to Prof. Dr. P.M. Schlag from the Charité
Comprehensive Cancer Center (CCCC) for supplying frozen samples and for
fruitful discussions. The authors thank Ms. Sabine Grigull, Ms. Bianca
Kochnowsky, Ms. Christina Krüger and Ms. Carola Meier for excellent
technical assistance and Dr. Wolfgang Haensch for careful pathological
review of the samples. This work was supported by a grant from the BMBF
“InnoRegio Gesundheitsregion Berlin-Buch”. Dr. Miguel Andrade
acknowledges funding from The Helmholtz Alliance on Systems Biology
(Helmholtz-Gemeinschaft Deutscher Forschungszentren). The sponsors were
not involved in any decisions regarding this study.
Author details
1Translational Oncology, Experimental Clinical Research Center, Charite
Campus Buch, Lindenberger Weg 80, D-13125 Berlin, Germany.
2Computational Biology and Data Mining group, Max Delbrueck Center for
Molecular Medicine, Robert Roessle Str. 10, D-13125 Berlin, Germany.
3Presently at Department for Computational Molecular Biology, Max Planck
Institute for Molecular Genetics, 14195 Berlin, Germany. 4Institut für
Integrative Anatomie, Charite Campus Mitte, Philippstr. 12, D-10115 Berlin,
Germany.
Received: 25 February 2013 Accepted: 29 January 2014
Published: 5 February 2014
References
1. Union E: Europe against Colorectal Cancer, Declaration of Brussels. European
Union: Brussels; 2007.
2. Markowitz SD, Bertagnolli MM: Molecular origins of cancer: molecular
basis of colorectal cancer. N Engl J Med 2009, 361:2449–2460.
3. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling
N: Colorectal cancer. Lancet 2010, 375:1030–1047.
4. Wang Y, Jatkoe T, Zhang Y, Mutch MG, Talantov D, Jiang J, McLeod HL,
Atkins D: Gene expression profiles and molecular markers to predict
recurrence of Dukes' B colon cancer. J Clin Oncol 2004, 22:1564–1571.
5. Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A, Coppola D,
Kruhoffer M, Aaltonen L, Orntoft TF, Quackenbush J, Yeatman TJ: Molecular
staging for survival prediction of colorectal cancer patients. J Clin Oncol
2005, 23:3526–3535.
6. Arango D, Laiho P, Kokko A, Alhopuro P, Sammalkorpi H, Salovaara R,
Nicorici D, Hautaniemi S, Alazzouzi H, Mecklin JP, Jarvinen H, Hemminki A,
Astola J, Schwartz S Jr, Aaltonen LA: Gene-expression profiling predicts
recurrence in Dukes' C colorectal cancer. Gastroenterology 2005,
129:874–884.
7. Pillaire MJ, Selves J, Gordien K, Gourraud PA, Gentil C, Danjoux M, Do C,
Negre V, Bieth A, Guimbaud R, Trouche D, Pasero P, Mechali M, Hoffmann
JS, Cazaux C: A 'DNA replication' signature of progression and negative
outcome in colorectal cancer. Oncogene 2010, 29:876–887.
8. Jorissen RN, Gibbs P, Christie M, Prakash S, Lipton L, Desai J, Kerr D,
Aaltonen LA, Arango D, Kruhoffer M, Orntoft TF, Andersen CL, Gruidl M,
Kamath VP, Eschrich S, Yeatman TJ, Sieber OM: Metastasis-Associated Gene
Expression Changes Predict Poor Outcomes in Patients with Dukes
Stage B and C Colorectal Cancer. Clin Cancer Res 2009, 15:7642–7651.
9. Barrier A, Lemoine A, Boelle PY, Tse C, Brault D, Chiappini F, Breittschneider
J, Lacaine F, Houry S, Huguier M, Van der Laan MJ, Speed T, Debuire B,
Flahault A, Dudoit S: Colon cancer prognosis prediction by gene
expression profiling. Oncogene 2005, 24:6155–6164.
10. Barrier A, Boelle PY, Roser F, Gregg J, Tse C, Brault D, Lacaine F, Houry S,
Huguier M, Franc B, Flahault A, Lemoine A, Dudoit S: Stage II colon cancer
prognosis prediction by tumor gene expression profiling. J Clin Oncol
2006, 24:4685–4691.
11. Zhang X, Lu X, Shi Q, Xu XQ, Leung HC, Harris LN, Iglehart JD, Miron A, Liu
JS, Wong WH: Recursive SVM feature selection and sample classification
for mass-spectrometry and microarray data. BMC Bioinformatics 2006,
7:197.
12. Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays
applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001,
98:5116–5121.
13. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B,
Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R,
Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney
Fehlker et al. BMC Cancer 2014, 14:64 Page 12 of 12
http://www.biomedcentral.com/1471-2407/14/64L, Yang JY, Zhang J: Bioconductor: open software development for
computational biology and bioinformatics. Genome Biol 2004, 5:R80.
14. Huber W, von Heydebreck A, Sueltmann H, Poustka A, Vingron M:
Parameter estimation for the calibration and variance stabilization of
microarray data. Stat Appl Genet Mol Biol 2003, 2:Article3.
15. Kauffmann A, Gentleman R, Huber W: arrayQualityMetrics–a bioconductor
package for quality assessment of microarray data. Bioinformatics 2009,
25:415–416.
16. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I: Controlling the false
discovery rate in behavior genetics research. Behav Brain Res 2001,
125:279–284.
17. Falcon S, Gentleman R: Using GOstats to test gene lists for GO term
association. Bioinformatics 2007, 23:257–258.
18. Astrosini C, Roeefzaad C, Dai YY, Dieckgraefe BK, Jons T, Kemmner W:
REG1A expression is a prognostic marker in colorectal cancer and
associated with peritoneal carcinomatosis. Int J Cancer 2008, 123:409–413.
19. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using
real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods
2001, 25:402–408.
20. Jass JR: Classification of colorectal cancer based on correlation of clinical,
morphological and molecular features. Histopathology 2007, 50:113–130.
21. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM,
Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M,
Gallinger S: Tumor microsatellite-instability status as a predictor of
benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
N Engl J Med 2003, 349:247–257.
22. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C,
Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P,
Cugnenc PH, Trajanoski Z, Fridman WH, Pages F: Type, density, and
location of immune cells within human colorectal tumors predict clinical
outcome. Science 2006, 313:1960–1964.
23. Salama P, Platell C: Host response to colorectal cancer. ANZ J Surg 2008,
78:745–753.
24. Kishimoto T, Saito K, Ishikura H: [Mechanism of blood-borne metastasis in
relation to the interaction between pancreatic carcinoma and
endothelial cells]. Nippon Rinsho 1995, 53:1765–1769.
25. Koda K, Saito N, Takiguchi N, Oda K, Nunomura M, Nakajima N:
Preoperative natural killer cell activity: correlation with distant
metastases in curatively research colorectal carcinomas. Int Surg 1997,
82:190–193.
26. Nagtegaal ID, Marijnen CA, Kranenbarg EK, Mulder-Stapel A, Hermans J, van
de Velde CJ, van Krieken JH: Local and distant recurrences in rectal cancer
patients are predicted by the nonspecific immune response; specific
immune response has only a systemic effect–a histopathological and
immunohistochemical study. BMC Cancer 2001, 1:7.
27. Nielsen HJ, Hansen U, Christensen IJ, Reimert CM, Brunner N, Moesgaard F:
Independent prognostic value of eosinophil and mast cell infiltration in
colorectal cancer tissue. J Pathol 1999, 189:487–495.
28. Canna K, McArdle PA, McMillan DC, McNicol AM, Smith GW, McKee RF,
McArdle CS: The relationship between tumour T-lymphocyte infiltration,
the systemic inflammatory response and survival in patients undergoing
curative resection for colorectal cancer. Br J Cancer 2005, 92:651–654.
29. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik
B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH,
Trajanoski Z, Fridman WH, Galon J: Effector memory T cells, early
metastasis, and survival in colorectal cancer. N Engl J Med 2005,
353:2654–2666.
30. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD: Cancer immunoediting:
from immunosurveillance to tumor escape. Nat Immunol 2002, 3:991–998.
31. Kloor M, Michel S: Immune evasion of microsatellite unstable colorectal
cancers. Int J Cancer 2010, 127:1001–1010.
32. Lovig T, Andersen SN, Thorstensen L, Diep CB, Meling GI, Lothe RA,
Rognum TO: Strong HLA-DR expression in microsatellite stable
carcinomas of the large bowel is associated with good prognosis.
Br J Cancer 2002, 87:756–762.
33. Bustin SA, Li SR, Phillips S, Dorudi S: Expression of HLA class II in colorectal
cancer: evidence for enhanced immunogenicity of microsatellite-
instability-positive tumours. Tumour Biol 2001, 22:294–298.
34. Ramaswamy S, Ross KN, Lander ES, Golub TR: A molecular signature of
metastasis in primary solid tumors. Nat Genet 2003, 33:49–54.35. Matoba K, Iizuka N, Gondo T, Ishihara T, Yamada-Okabe H, Tamesa T, Takemoto
N, Hashimoto K, Sakamoto K, Miyamoto T, Uchimura S, Hamamoto Y, Oka M:
Tumor HLA-DR expression linked to early intrahepatic recurrence of
hepatocellular carcinoma. Int J Cancer 2005, 115:231–240.
36. Network CGA: Comprehensive genomic characterization of squamous
cell lung cancers. Nature 2012, 489:519–525.
37. Van Gool SW, Vandenberghe P, De BM, Ceuppens JL: CD80, CD86 and
CD40 provide accessory signals in a multiple-step T-cell activation
model. Immunol Rev 1996, 153:47–83.
38. Kodelja V, Muller C, Politz O, Hakij N, Orfanos CE, Goerdt S: Alternative
macrophage activation-associated CC-chemokine-1, a novel structural
homologue of macrophage inflammatory protein-1 alpha with a
Th2-associated expression pattern. J Immunol 1998, 160:1411–1418.
39. Leung SY, Yuen ST, Chu KM, Mathy JA, Li R, Chan AS, Law S, Wong J, Chen
X, So S: Expression profiling identifies chemokine (C-C motif) ligand 18
as an independent prognostic indicator in gastric cancer.
Gastroenterology 2004, 127:457–469.
40. Schutyser E, Richmond A, Van-Damme J: Involvement of CC chemokine
ligand 18 (CCL18) in normal and pathological processes. J Leukoc Biol
2005, 78:14–26.
41. Sun B, Nishihira J, Yoshiki T, Kondo M, Sato Y, Sasaki F, Todo S: Macrophage
migration inhibitory factor promotes tumor invasion and metastasis via
the Rho-dependent pathway. Clin Cancer Res 2005, 11:1050–1058.
42. Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler
C, Werner ER, Werner-Felmayer G, Weiss HG, Gobel G, Margreiter R,
Konigsrainer A, Fuchs D, Amberger A: Prognostic value of indoleamine
2,3-dioxygenase expression in colorectal cancer: effect on
tumor-infiltrating T cells. Clin Cancer Res 2006, 12:1144–1151.
43. Ishio T, Goto S, Tahara K, Tone S, Kawano K, Kitano S: Immunoactivative
role of indoleamine 2,3-dioxygenase in human hepatocellular carcinoma.
J Gastroenterol Hepatol 2004, 19:319–326.
44. Riesenberg R, Weiler C, Spring O, Eder M, Buchner A, Popp T, Castro M,
Kammerer R, Takikawa O, Hatz RA, Stief CG, Hofstetter A, Zimmermann W:
Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells
correlates with long-term survival of patients with renal cell carcinoma.
Clin Cancer Res 2007, 13:6993–7002.
45. Lob S, Konigsrainer A, Rammensee HG, Opelz G, Terness P: Inhibitors of
indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood
for the trees? Nat Rev Cancer 2009, 9:445–452.
46. Lin YH, Friederichs J, Black MA, Mages J, Rosenberg R, Guilford PJ, Phillips V,
Thompson-Fawcett M, Kasabov N, Toro T, Merrie AE, van Rij A, Yoon HS,
McCall JL, Siewert JR, Holzmann B, Reeve AE: Multiple gene expression
classifiers from different array platforms predict poor prognosis of
colorectal cancer. Clin Cancer Res 2007, 13:498–507.
47. Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A,
Camus M, Gillard M, Bruneval P, Fridman WH, Pages F, Trajanoski Z, Galon J:
Biomolecular network reconstruction identifies T-cell homing factors
associated with survival in colorectal cancer. Gastroenterology 2010,
138:1429–1440.
48. Specht K, Harbeck N, Smida J, Annecke K, Reich U, Naehrig J, Langer R,
Mages J, Busch R, Kruse E, Klein-Hitpass L, Schmitt M, Kiechle M, Hoefler H:
Expression profiling identifies genes that predict recurrence of breast
cancer after adjuvant CMF-based chemotherapy. Breast Cancer Res Treat
2008, 118:45–56.
49. Michielsen AJ, Noonan S, Martin P, Tosetto M, Marry J, Biniecka M, Maguire
AA, Hyland JM, Sheahan KD, O'Donoghue DP, Mulcahy HE, Fennelly D, Ryan
EJ, O'Sullivan JN: Inhibition of dendritic cell maturation by the tumor
microenvironment correlates with the survival of colorectal cancer
patients following bevacizumab treatment. Mol Cancer Ther 2012,
11:1829–1837.
50. Michielsen AJ, Hogan AE, Marry J, Tosetto M, Cox F, Hyland JM, Sheahan KD,
O'Donoghue DP, Mulcahy HE, Ryan EJ, O'Sullivan JN: Tumour tissue
microenvironment can inhibit dendritic cell maturation in colorectal
cancer. PLoS One 2011, 6:e27944.
doi:10.1186/1471-2407-14-64
Cite this article as: Fehlker et al.: Concerted down-regulation of
immune-system related genes predicts metastasis in colorectal
carcinoma. BMC Cancer 2014 14:64.
